Home / Therapies / Blood Glucose Control / Less Insulin, More Weight Loss? A New Type 1 Diabetes Drug Shows Early Promise

Less Insulin, More Weight Loss? A New Type 1 Diabetes Drug Shows Early Promise

Nov 15, 2026
742 views
 

Could an added treatment help adults with type 1 diabetes lose weight without dangerous glucose swings? An early clinical trial of acmopatide in adults with type 1 diabetes offers some clues. Over 16 weeks, the investigational once-daily injection helped some participants lose weight and reduce insulin requirements. However, A1C improvements varied by dose, and important safety questions remain.

Table of Contents

  • Why Another Type 1 Diabetes Treatment Matters
  • How Acmopatide Affected A1C and Weight in Type 1 Diabetes
  • Less Daily Insulin, but Not at Every Dose
  • Side Effects, Ketosis Risks, and the Road Ahead
  • Conclusion
  • Frequently Asked Questions

Why Another Type 1 Diabetes Treatment Matters

Insulin remains essential for people with type 1 diabetes. However, managing blood glucose becomes more challenging when excess weight and insulin resistance are also present. Some adults need higher insulin doses, which may contribute to further weight gain and complicate daily treatment.

 

As a result, researchers are exploring medications that might improve metabolic health while supporting traditional insulin therapy.

Acmopatide, also known as CT-868, is an investigational drug that targets two hormone pathways: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones help regulate appetite, digestion, and blood glucose responses after meals.

Unlike insulin, acmopatide does not replace the hormone that people with type 1 diabetes cannot produce adequately. Instead, researchers are investigating whether it could serve as an additional treatment.

Previous research has examined GLP-1 receptor agonists in type 1 diabetes, although concerns about hypoglycemia, ketosis, and gastrointestinal symptoms have limited their routine use.

The new Phase 2 randomized trial, published in Diabetes Care on October 28, 2026, included 111 adults across 22 U.S. centers.

Participants had type 1 diabetes, a body mass index of at least 27, and an A1C between 7% and 10%. They received either placebo or acmopatide targeting daily doses of 1.8 mg, 4.1 mg, or 6.6 mg.

Researchers then assessed changes in A1C, body weight, and daily insulin requirements.

How Acmopatide Affected A1C and Weight in Type 1 Diabetes

One of the trial's most interesting findings involved the relationship between dose and glucose control. Surprisingly, the middle dose produced the clearest A1C benefit.

After 16 weeks, participants receiving 4.1 mg experienced an average A1C reduction of 0.59 percentage points. Meanwhile, the placebo group showed a reduction of 0.25 points.

The placebo-adjusted difference was approximately 0.34 percentage points, with a nominal P value of 0.020.

Additionally, about 56% of participants receiving 4.1 mg achieved an A1C below 7%, compared with 33% receiving placebo.

However, the other doses produced less convincing results. A1C declined by 0.43 percentage points with 1.8 mg and 0.45 points with 6.6 mg. Neither demonstrated a clear advantage over placebo.

These findings suggest that increasing the dose does not necessarily improve glucose control.

Weight loss results were more consistent. Participants receiving 1.8 mg lost approximately 3.3% of their starting body weight. Those receiving 4.1 mg lost 6.4%, while the 6.6-mg group lost 6.7%.

In comparison, placebo recipients gained approximately 0.3%.

Furthermore, 63% of participants in each higher-dose group lost at least 5% of their starting body weight, compared with just 7% receiving placebo.

These results suggest that acmopatide may offer meaningful weight-management benefits for selected adults with type 1 diabetes and overweight or obesity.

Less Daily Insulin, but Not at Every Dose

Reducing insulin requirements without compromising glucose control is another potential benefit of adjunct diabetes medications.

In this trial, participants receiving 4.1 mg reduced their total daily insulin use by approximately 9.8%. Those receiving 6.6 mg experienced a larger reduction of 21.3%.

However, the placebo group also reduced insulin use by 6.4%, while participants receiving 1.8 mg showed a slight increase.

After accounting for placebo changes, insulin reductions were approximately 3.4% greater with 4.1 mg and 14.9% greater with 6.6 mg.

Although these findings were encouraging, the confidence intervals included no difference. In addition, incomplete insulin records limited the reliability of some estimates.

Consequently, researchers cannot yet determine how consistently acmopatide reduces insulin requirements.

Continuous glucose monitoring also suggested improvements in time spent within the recommended glucose range. Nevertheless, differences between treatment groups were uncertain.

Importantly, time spent below the glucose target appeared similar across groups.

For clinicians, these findings highlight the potential for improved weight management and lower insulin requirements. However, insulin adjustments must remain individualized, particularly because excessive reductions can increase the risk of ketosis and diabetic ketoacidosis.

Side Effects, Ketosis Risks, and the Road Ahead

Like other medications that act on GLP-1 pathways, acmopatide caused gastrointestinal side effects.

Among treated participants, approximately 48% reported nausea, 29% experienced constipation, and 24% reported vomiting.

Most symptoms were mild or moderate. Nevertheless, nearly 29% required temporary treatment interruptions or dose adjustments.

Additionally, only 17 of the 27 participants assigned to the 6.6-mg group successfully reached their target dose.

These findings raise practical questions about tolerability, especially when using higher doses.

No diabetic ketoacidosis or severe hypoglycemia events occurred during the study. However, nonsevere hypoglycemia was reported as an adverse event in 18% of treated participants, compared with 7% receiving placebo.

Participants also received ketone monitoring supplies and instructions for checking ketones when glucose levels were elevated or symptoms suggested ketosis.

Therefore, the absence of diabetic ketoacidosis should not be interpreted as proof that acmopatide eliminates this risk.

Several limitations also deserve attention. The study lasted only 16 weeks and included a relatively small population. Most participants were White, while individuals with recent severe hypoglycemia or diabetic ketoacidosis were excluded.

Future studies would need to determine whether the benefits persist over time and whether similar outcomes occur in more diverse populations.

Importantly, American Diabetes Association Scientific Sessions coverage reported that the manufacturer does not plan to advance acmopatide into Phase 3 development.

Consequently, these findings may contribute more to future diabetes drug research than to an immediate new treatment option.

Patients interested in emerging therapies should discuss potential benefits and risks with their diabetes care team. Additional professional guidance is also available through Healthcare.pro.

Conclusion

The trial suggests acmopatide may help some adults with type 1 diabetes lose weight and reduce their insulin needs.

At 4.1 mg, the medication produced its clearest A1C benefit. Meanwhile, the 6.6-mg dose produced the greatest reductions in body weight and daily insulin use.

However, gastrointestinal side effects, uncertain insulin-use estimates, and limited follow-up remain important concerns.

Although acmopatide is unlikely to move directly toward approval under current development plans, its findings offer useful insights into future adjunct treatments for type 1 diabetes.

For now, insulin remains essential, and any additional medication requires careful clinical evaluation.

Frequently Asked Questions

1. What is acmopatide?

Acmopatide, also called CT-868, is an investigational dual GLP-1/GIP receptor agonist. Researchers have studied it as an additional treatment for adults with type 1 diabetes and overweight or obesity.

2. Did acmopatide improve A1C in people with type 1 diabetes?

Yes. A1C improved in the treatment groups, but the clearest placebo-adjusted benefit occurred with the 4.1-mg dose. Higher doses did not consistently produce better glucose control.

3. How much weight did participants lose during the trial?

Average weight loss ranged from approximately 3.3% to 6.7% over 16 weeks, depending on the acmopatide dose. By comparison, the placebo group experienced a small average weight increase.

4. Does acmopatide reduce the amount of insulin patients need?

The 4.1-mg and 6.6-mg groups showed reductions in total daily insulin use. However, uncertainty in the results means larger studies would be needed to confirm this benefit. Acmopatide cannot replace insulin therapy.

5. Will acmopatide undergo further clinical trials for type 1 diabetes?

The manufacturer has reportedly decided not to advance acmopatide into Phase 3 development. Nevertheless, the Phase 2 findings may help guide research into other GLP-1/GIP-based treatments for type 1 diabetes.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.